This proof-of-concept study outlines a scalable method for developing PCR-based tissue-specific cfDNA biomarkers. Our kidney-specific assay demonstrates the potential for rapid, cost-effective organ injury monitoring and could be adapted for other tissue types. This strategy may support future diagnostic applications in nephrology, oncology, and transplant medicine.
Murray et al. (Mon,) studied this question.